Welcome to Typography 2. I am excited to meet (or re-meet with) all of you!
Day One Prep: Please bring a) laptop with InDesign, b) syllabus, and c) textbook worksheets found in the Handouts section in the navigation above.
In class on Monday there will be a typesetting assignment. We will typeset the two texts you will find after the jump. Use Bringhurst’s style guidelines (here they are for website design).
Why refesh our fine typesetting skills? Professional designers are expected to demonstrate fine typesetting skills, expert level, especially at the micro level (details, analaphabetic characters, etc). Please refer to: “Typelesson.pdf” by Nick Shin for assistance.
You can find the copy for the typesetting assignment 2a after the jump…
Partner Update: Annual report highlights
Gilead Partners
Pfizer Inc
In August 1996, Gilead and Pharmacia & Upjohn (now Pfizer) entered into a collaboration whereby Pharmacia was given exclusive rights to market VISTIDE® (cidofovir injection) for the treatment of cytomegalovirus retinitis in patients with HIV in all countries outside of the United States. Under the terms of the agreement, Pharmacia paid Gilead a $10 million initial license fee, and an additional $10 million milestone payment upon receipt of the European Marketing Authorisation for VISTIDE in May 1997. Pfizer also pays Gilead royalty payments on sales of VISTIDE. In addition, as a result of receiving the European Marketing Authorisation, Pharmacia purchased 1,133,786 shares of newly issued Series B Convertible Preferred Stock for approximately $40 million or $35.28 per share.
Japan Tobacco Inc
In July 2003, Gilead Sciences and Japan Tobacco Inc. (JT) entered into a licensing agreement under which JT will commercialize products in Gilead’s HIV portfolio in Japan. The agreement includes Viread® (tenofovir disoproxil fumarate), Emtriva® (emtricitabine) and the co-formulation of the two products, Truvada® (tenofovir disoproxil fumarate and emtricitabine). JT is responsible for seeking regulatory approval and commercialization of all three products in Japan. Upon successful commercialization of the products in Japan, JT will make payments to Gilead based on product sales. In April 2004, JT announced the launch of Viread in Japan.
Cubist Pharmaceuticals
Cambridge, MA and Foster City, CA, January 7, 2001 - Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) and Gilead Sciences, Inc. (Nasdaq: GILD) jointly announced the signing of a licensing agreement for the exclusive rights to commercialize Cubist’s investigational antibacterial drug CidecinTM (daptomycin for injection) and an oral formulation of daptomycin in 16 European countries following regulatory approval.
2)
MR. STEVEN’s MONDAY
Mr. Stevens scurried to - and fro trying to get the 14 1/2” x 40” box prepared for the U.P.S. driver. The U.P.S. driver was standing at the door, politely waiting for Mr. Stevens to get the box taped up and addressed. Mr. Stevens was sending the package to Lynn Lee, M.D.’ F.R.C.S.(C) at 4444 Wondering WAy, Toronto, ON M5R 2R6. Mr. Stevens was quite concerned that the package might not leave on time. This past week his town experienced a flood and a few days later a tornado touched down. Today, he was more than fairly certain - as bad things come in threes - that a third natural disaster was about to hit.
..........
In class assignment #2: Online research on expressive typographic constructions.
Comments